Clinical-stage biotech developing EVX-101, a 5-HTP based adjunctive therapy for depression and obsessive-compulsive disorder.
At a glance
- HQ: RTP
- Sector: Biotech
- Stage: Growth
- Total raised: $4.6M
Funding sources
Sources attached to recorded funding rounds.
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Listed roles
All Triangle rolesChecking listed roles…